Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Prepaid Assets (2016 - 2025)

ImmunityBio (IBRX) has disclosed Prepaid Assets for 11 consecutive years, with $1.3 million as the latest value for Q4 2024.

  • On a quarterly basis, Prepaid Assets fell 94.91% to $1.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $1.3 million, a 94.91% decrease, with the full-year FY2024 number at $1.3 million, down 94.91% from a year prior.
  • Prepaid Assets was $1.3 million for Q4 2024 at ImmunityBio, down from $25.9 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $31.5 million in Q4 2022 to a low of $569000.0 in Q1 2021.
  • A 5-year average of $12.7 million and a median of $9.0 million in 2020 define the central range for Prepaid Assets.
  • Peak YoY movement for Prepaid Assets: soared 965.37% in 2022, then plummeted 94.91% in 2024.
  • ImmunityBio's Prepaid Assets stood at $13.6 million in 2020, then crashed by 78.34% to $3.0 million in 2021, then skyrocketed by 965.37% to $31.5 million in 2022, then decreased by 18.73% to $25.6 million in 2023, then tumbled by 94.91% to $1.3 million in 2024.
  • Per Business Quant, the three most recent readings for IBRX's Prepaid Assets are $1.3 million (Q4 2024), $25.9 million (Q3 2024), and $21.0 million (Q2 2024).